GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » Debt-to-Revenue

Grand Pharmaceutical Group (HKSE:00512) Debt-to-Revenue : 0.38 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Grand Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$2,353 Mil. Grand Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,052 Mil. Grand Pharmaceutical Group's annualized Revenue for the quarter that ended in Dec. 2023 was HK$9,080 Mil. Grand Pharmaceutical Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.37.


Grand Pharmaceutical Group Debt-to-Revenue Historical Data

The historical data trend for Grand Pharmaceutical Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group Debt-to-Revenue Chart

Grand Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.38 0.42 0.47 0.32

Grand Pharmaceutical Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.34 0.51 0.35 0.38

Competitive Comparison of Grand Pharmaceutical Group's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grand Pharmaceutical Group's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's Debt-to-Revenue falls into.



Grand Pharmaceutical Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Grand Pharmaceutical Group's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2352.597 + 1051.642) / 10529.59
=0.32

Grand Pharmaceutical Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2352.597 + 1051.642) / 9080.208
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Grand Pharmaceutical Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Grand Pharmaceutical Group (HKSE:00512) Business Description

Traded in Other Exchanges
Address
99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG
Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines